ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
20 announcements
Amerise Biosciences Limited conducted its 41st Annual General Meeting on September 24, 2026. Shareholders approved financial statements and the appointment of a new Wholetime Director and CFO.
Amerise Biosciences has submitted its Annual Report for the financial year 2024-25. The company scheduled its 41st Annual General Meeting for September 24, 2026.
Amerise Biosciences Ltd has submitted the notice for its 41st Annual General Meeting, scheduled to be held on September 24, 2026.
Snehjeev Ventures Private Limited and PACs acquired 76,725 equity shares of Amerise Biosciences Ltd. The acquisition increases their aggregate stake from 10.92% to 11.04%.
Amerise Biosciences Limited has appointed Ms. Soni Pandiya as the new Company Secretary, replacing Ms. Minal Lakhani who resigned for better career opportunities.
Amerise Biosciences Ltd reported a net loss of ₹0.1 Cr for Q1 FY27.
Snehjeev Ventures Pvt. Ltd. and PACs increased their stake in Amerise Biosciences Ltd by 0.04% through an open market purchase, reaching 9.02% total holding.
Amerise Biosciences Ltd has scheduled a Board Meeting on 3rd August 2026 to consider and approve the un-audited financial results for the quarter ended 30th June 2026.
Snehjeev Ventures Private Limited sold 3,18,285 shares of Amerise Biosciences in the open market. Their holding reduced from 9.31% to 8.83%.
Snehjeev Ventures Pvt Ltd acquired a 0.06% stake in Amerise Biosciences via open market. This increases their total holding to 9.04% of the company.
Snehjeev Ventures Pvt Ltd acquired 32,000 shares of Amerise Biosciences Ltd via open market. The non-promoter group's total holding increased to 7.04%.
Amerise Biosciences Ltd reported revenue from operations of ₹0.1 Cr (-50.0% YoY) and net profit of ₹0.1 Cr (+0.0% YoY) for Q4 FY26.
Amerise Biosciences Ltd reported audited standalone financial results for the year ended March 31, 2026, with total income of ₹0.26 Crore and a net profit of ₹0.016 Crore. The board approved these results in a meeting concluded on May 5, 2026. The auditor issued an unmodified opinion on the performance.
Snehjeev Ventures Pvt Ltd and PACs acquired 5,60,000 equity shares (0.85% stake) of Amerise Biosciences Ltd via the open market. This acquisition increases their total holding from 4.49% to 5.34%, crossing the 5% regulatory threshold.
Snehjeev Ventures Pvt Ltd acquired 5,60,000 equity shares of Amerise Biosciences Ltd via the open market. This acquisition increased their total holding to 35,29,664 shares (5.34%), crossing the 5% statutory disclosure threshold. The acquirer is a non-promoter entity, and the transaction was completed on April 24, 2026.
Amerise Biosciences Ltd has scheduled a Board of Directors meeting for May 5, 2026. The board will primarily consider and approve the audited standalone financial results for the quarter and year ended March 31, 2026.
Amerise Biosciences Limited confirmed it does not fall under the Large Corporate category as per SEBI's debt issuance framework for the financial year ended March 31, 2026. Consequently, the company is not required to submit initial or annual disclosures under the specific SEBI circular.
Amerise Biosciences Ltd announced that Ms. Soni Pandiya has been appointed as Company Secretary and Compliance Officer effective April 15, 2026. This follows the resignation of Ms. Minal Lakhlani from the same position due to personal reasons. Ms. Pandiya brings over six years of experience in secretarial and legal functions to the role.
Amerise Biosciences Limited (BSE: 531681) submitted a certificate confirming the non-applicability of the Annual Secretarial Compliance Report for FY 2025-26. The company is exempt under SEBI Regulation 15(2) as its paid-up capital and net worth remain below the prescribed thresholds of ₹10 Crore and ₹25 Crore, respectively.
Amerise Biosciences Limited submitted its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the period ended March 31, 2026. The Registrar and Share Transfer Agent confirmed that no physical share certificates were received for dematerialization during the quarter.